Document is current
Any future updates will be listed below
-
Authors
Cowan, Tovah https://orcid.org/0000-0002-0169-6412
Rodriguez, Zachary B. https://orcid.org/0000-0002-4591-803X
Strauss, Gregory P.
Raugh, Ian M. https://orcid.org/0000-0003-4981-2395
Cohen, Alex S. https://orcid.org/0000-0003-4014-6904
-
Funding
Funding for this research was provided by:
National Institute of Mental Health (R21 MH112925)
- License Information
-
More Information
Article History
Received: 1 May 2023
Accepted: 20 September 2023
First Online: 25 October 2023
Declarations
:
: G. P. Strauss is one of the original developers of the Brief Negative Symptom Scale (BNSS) and receives royalties and consultation fees from ProPhase LLC in connection with commercial use of the BNSS and other professional activities; these fees are donated to the Brain and Behavior Research Foundation. Dr. Strauss has received honoraria and travel support from ProPhase LLC for training pharmaceutical company raters on the BNSS. In the past 2 years, Dr. Strauss has consulted for and/or been on the speaker bureau for Minerva Neurosciences, Acadia, Sunovion, Otsuka, Boehringer-Ingelheim, and Lundbeck pharmaceutical companies. In the past 2 years, Dr. Cohen has received honoraria and support from Quantic Innovation and has provided consulting services to Sunovion, Karuna, Boehringer-Ingelheim, and Indivior.
: The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and the Helsinki Declaration of 1975, as revised in 2008.
: Informed consent was obtained from all subjects involved in this study.
